Testing BNT113 plus pembrolizumab versus pembrolizumab alone
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to and sign the trial’s pre-screening consent form before any study checks.
- Your cancer must be recurrent or metastatic HPV16-positive head and neck squamous cancer that isn’t curable with local treatments.
- Your tumor test must show PD-L1 positivity (CPS 1 or higher) using an approved lab test (22C3).
- You cannot have had prior cancer medicines that treat the whole body for this incurable recurrent/metastatic situation (treatment over 180 days ago for some earlier local cancers may be allowed).
- You need at least one measurable tumor spot on scans (and certain past radiation-area spots may count if they’ve clearly grown).
- You must provide a tumor tissue sample from a past biopsy or surgery (or a fresh biopsy if that’s standard for you before starting treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial is testing a combination of two investigational drugs (VB10 and pembrolizumab) in patients with a specific type of head and neck cancer that has returned or spread. The goal is to see if this treatment is safe and effective.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Hear when a new Unresectable Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.